Equities

Precigen Inc

Precigen Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.9015
  • Today's Change-0.001 / -0.16%
  • Shares traded720.15k
  • 1 Year change-20.92%
  • Beta1.6910
Data delayed at least 15 minutes, as of Nov 22 2024 20:46 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Precigen Inc's revenues fell -76.87%from 26.91m to 6.23m. In addition, the company has been unable to reduce the cost of goods sold, selling, general and administrative expenses and interest paid (all as a percentage of sales). This has contributed to a reduction in net income from a gain of 28.32m to a loss of 95.90m.
Gross margin-12.44%
Net profit margin-3,521.68%
Operating margin-3,551.30%
Return on assets-101.81%
Return on equity-137.46%
Return on investment-126.84%
More ▼

Cash flow in USDView more

In 2023, cash reserves at Precigen Inc fell by 40.75m. Cash Flow from Financing totalled 29.59m or 475.33% of revenues. In addition the company used 66.93m for operations while cash used for investing totalled 3.09m.
Cash flow per share-0.5226
Price/Cash flow per share--
Book value per share0.1891
Tangible book value per share0.0877
More ▼

Balance sheet in USDView more

Precigen Inc uses little or no debt in its capital structure.
Current ratio1.63
Quick ratio--
Total debt/total equity0.00
Total debt/total capital0.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.